2nd
The Alliance for mRNA Medicines (AMM) brings together senior executives and top decision-makers in the mRNA industry to advance pioneering research into vaccines and therapies for patients. The annual meeting, AMM ASCENT (Advancements in mRNA Science, Commercialization, Education, and Novel Technologies), features one-on-one partnering opportunities for companies and investors, dedicated networking, keynotes and fireside chats featuring KOLs and industry visionaries, as well as engaging plenary and panel discussions among biotech, pharma, and academic leaders.
September 16-18, 2025
Coronado Island Marriott Resort and Spa
2000 2nd St, Coronado, CA 92118
Through the power of the partneringONE partnering platform, attendees can search, connect, and schedule 1:1 meetings with potential partners to identify opportunities, build relationships, and move deals forward.
Ample dedicated networking opportunies to connect with other industry leaders and potential partners.
Learn from senior executives and top decision-makers in the mRNA industry to advance pioneering research into vaccines and therapies for patients with engaging speakers, fireside chats, and panel discussions.
Our sessions will feature some of the leading voices in the mRNA industry, sharing their unique insights and expertise. Currently confirmed speakers include:
Executive Director, AMM
Chief Business Officer, Nutcracker Therapeutics
Chief Science Officer, Orbital Therapeutics
Chief Innovation Officer, Maravai Life Sciences
Chief Translational Sciences Officer, Houston Methodist
Chief Strategy Officer, Arcturus Therapeutics
Chief Development Officer, Replicate Bioscience
Associate Vice President, Eli Lilly
Chief Scientific Officer, Aldevron
Chief Technology Officer, Danaher Corporation
Senior Vice President RNA Biochemistry & Manufacturing, BioNTech
Director, Chemistry, Manufacturing & Controls, Acuitas Therapeutics
Global CMC Manager, Wacker
Vice President, Preclinical Development, Acuitas Therapeutics
ML Lead, Terrain Biosciences
Founder & CEO, RNAV8 Bio
Managing Director, AMM
Senior Advisor, AMM
Our sessions will feature some of the leading voices in the mRNA industry, sharing their unique insights and expertise. Currently confirmed speakers include:
Director, Center for Biologics Evaluation and Research, FDA
Deputy Center Director, Center for Biologics Evaluation and Research, FDA
Chief Development Officer and Co-Founder, Replicate Bioscience
Executive Director, AMM
Co-founder and Director of Research and Quality Development, ExploRNA
AMM Co-founder and Board Chair, Foundation for mRNA Medicines
CEO, Ribbon Bio
Chief Business Officer, Nutcracker Therapeutics
Chief Science Officer, Orbital Therapeutics
Business Development Manager, Hongene Biotech Corporation
Bloomberg Distinguished Professor of RNA Biology and Therapeutics, Johns Hopkins University
Chief Translational Sciences Officer & Medical Director for RNA Therapeutics, Houston Methodist
North American Sales and Applications Manager, NanoFCM
Chief Strategy Officer, Arcturus Therapeutics
Professor in Residence, Physiology and Biophysics, UC Irvine School of Medicine
President, Uncommon Cures
CEO and Co-Founder, Sensible
Chief Development Officer, Replicate Bioscience, AMM Board Chair
CEO, La Jolla Labs
Associate Vice President, Eli Lilly
Senior Director, Scientific Solutions, Charles River
Chief Scientific Officer, Aldevron
CSO/CTO, Danaher Genomic Medicines
Professor, Al-Faisal University
SVP Biochemistry and Manufacturing, BioNTec
Biopharmaceutical Services and Non-Viral Delivery Business Leader, Cytiva
VP, Marketing and Corporate Development, Nature’s Toolbox
Director of R&D, Syvento
Sr. Director, Chemistry, Manufacturing & Controls, Acuitas Therapeutics
CEO, Radar Therapeutics
SVP Corporate Development, PharmaJet
former Director, Center for Biologics Evaluation and Research, US Food and Drug Administration
Professor of Cell & Gene Therapy, University College London
CEO, Cytonus
PharmD, Executive Director, U.S. Oncology Marketing Leader, Merck
VP, Head of Manufacturing, Sail Biomedicines
Innovation and Development Supervisor, Anemocyte
Senior Advisor, AMM
Director, Global Regulatory Science, Policy, and Intelligence, CSL Behring
Global CMC Manager, Wacker Biotech
Vice President, Preclinical Research, Acuitas Therapeutics
ML Lead, Terrain Biosciences
Founder & CEO, RNAV8 Bio
Managing Director, AMM
Director of Business Development, ExploRNA
Principal, Leavitt Partners and former Deputy Director, FDA Center for Biologics Evaluation and Research
Director, RNA and Formulation Core, University of British Columbia
Director Technology & Translation, Innovative Genomics Institute
Senior Director, Research and Economic Development, San Diego Economic Development Corporation
CEO, Replicate Bioscience
Editorial and Community Director, Advancing RNA
Professor of Cellular and Molecular Medicine, University of California San Diego
Chief Regulatory Officer, Arcturus Therapeutics
CEO of Primrose Bio
Breakfast
AMM Board Meeting (Board Members Only)
Partnering and Exhibits Open
Conference Opening and Welcome
Global Industry Outlook for mRNA
Fireside Chat: What’s Next After Baby KJ? The Future of mRNA in Gene Editing and Rare Disease
Lunch
Presentation and Discussion Session: Innovation in mRNA and Cancer Immunotherapies
Break
Global Regulatory Outlook for mRNA Products
Large Cap/Biopharm’s Role in mRNA Commercialization
Break
Meeting the Moment in mRNA
Break
Opening Reception
Breakfast
Partnering and Exhibits Open
Turning Research to Reality: Translational Projects from Academia
Panel Discussion and Presentations
Moderator, Jeff Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics, Johns Hopkins University
Break
Three 15-Minute Company Presentations
Lunch and Networking
Future of AI in mRNA Development
Four 15-min Company Presentations
Break
mRNA Manufacturing, CMC, and Analytics
Break
Reception (Bayside Lawn)
Breakfast
mRNA Therapeutics: Understanding the Global Market
mRNA Delivery Innovation
Break
Our mRNA Future
Closing Remarks
AMM is grateful to the partners whose support is making AMM ASCENT possible. Interested in becoming a sponsor? Contact [email protected] to learn more and check out our sponsor prospectus here.
DIAMOND SPONSOR
PLATINUM SPONSORS
GOLD SPONSOR
SILVER SPONSORS
BRONZE SPONSORS
Advancing RNA is a Life Science Connect community focused on the rapidly evolving field of RNA-based therapeutics. It aims to provide valuable insights, discussions, and resources for professionals developing RNA-based drugs. Primary members of the community consist of individuals from biopharma organizations engaged in pre-BLA development, often in the pre-IND discovery stages. The community addresses various challenges in RNA therapy development, including analytical, quality, manufacturing, and regulatory issues. Additionally, Advancing RNA is positioned within the broader Life Science Connect network, allowing members to access additional resources as needed for their RNA therapy development journey.
Partnering is different from networking! It’s planning to meet because you have something to discuss rather than finding something to discuss because you happen to meet. Successful partnering is tied to pre-event preparation. With the support of EBD Group’s partneringONE™, arranging one-to-one meetings with your target companies is a breeze. Watch this webinar for tips.
Partnering is different from networking! It’s planning to meet because you have something to discuss rather than finding something to discuss because you happen to meet. Successful partnering is tied to pre-event preparation. With the support of EBD Group’s partneringONE™, arranging one-to-one meetings with your target companies is a breeze.
The Alliance for mRNA Medicines (AMM) is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society. Our mission is to propel the future of mRNA medicine, improve patients’ lives, and advance scientific knowledge by convening and empowering mRNA industry leaders, innovators, scientists, and other key stakeholders.